Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist's Point of View

J Nucl Med. 2017 Aug;58(8):1207-1209. doi: 10.2967/jnumed.117.194753. Epub 2017 May 18.

Authors

Boris A Hadaschik¹, Martin Boegemann²

Affiliations

¹ Department of Urology, University Hospital Essen, Essen, Germany; and [email protected].
² Department of Urology, University Hospital Münster, Münster, Germany.

PMID: 28522737
DOI: 10.2967/jnumed.117.194753

No abstract available

Publication types

Editorial

MeSH terms

Antigens, Surface / metabolism*
Diagnostic Imaging*
Glutamate Carboxypeptidase II / metabolism*
Humans
Male
Molecular Targeted Therapy*
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging*
Prostatic Neoplasms, Castration-Resistant / metabolism
Prostatic Neoplasms, Castration-Resistant / therapy*
Urologists*

Substances

Antigens, Surface
FOLH1 protein, human
Glutamate Carboxypeptidase II